BioAtla, Inc. (BCAB): Price and Financial Metrics


BioAtla, Inc. (BCAB): $2.47

-0.02 (-0.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BCAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BCAB Stock Price Chart Interactive Chart >

Price chart for BCAB

BCAB Price/Volume Stats

Current price $2.47 52-week high $12.15
Prev. close $2.49 52-week low $2.01
Day low $2.43 Volume 94,438
Day high $2.51 Avg. volume 776,002
50-day MA $3.54 Dividend yield N/A
200-day MA $6.00 Market Cap 92.89M

BioAtla, Inc. (BCAB) Company Bio


BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.


BCAB Latest News Stream


Event/Time News Detail
Loading, please wait...

BCAB Latest Social Stream


Loading social stream, please wait...

View Full BCAB Social Stream

Latest BCAB News From Around the Web

Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, March 23, 2023 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2022 and provide business highlights. Conference Call

Yahoo | March 16, 2023

BioAtla Announces Change in Executive Leadership

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will be leaving the Company to pursue a new opportunity as Chief Executive Officer at Viatris (Nasdaq: VTRS), a large, global healthcare pharmaceutical company. Scott will continue his relationship with BioA

Yahoo | February 27, 2023

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administrati

Yahoo | February 23, 2023

Recent uptick might appease BioAtla, Inc. (NASDAQ:BCAB) institutional owners after losing 56% over the past year

If you want to know who really controls BioAtla, Inc. ( NASDAQ:BCAB ), then you'll have to look at the makeup of its...

Yahoo | January 25, 2023

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is being initiated; anticipate first patient dosed this quarter BA3071 Phase 1 study ongoing with first two dose escalation cohorts completed; third cohort (70mg) on-going CAB clinical programs continue

Yahoo | January 10, 2023

Read More 'BCAB' Stories Here

BCAB Price Returns

1-mo -33.60%
3-mo -70.38%
6-mo -71.54%
1-year -57.19%
3-year N/A
5-year N/A
YTD -70.06%
2022 -57.97%
2021 -42.28%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7143 seconds.